Award

09150161810003

Funder: ZonMw

Funded outputs count: 8

Funder award ID: 09150161810003

OpenAlex ID: G2819703475

Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy

2026 · Asli Özkan, Marieke IJsselsteijn, et al. · Journal for ImmunoTherapy of Cancer

Impact of geriatric impairments on outcomes of single‐agent immunotherapy in solid tumors

2025 · Asli Özkan, Karlijn de Joode, et al. · International Journal of Cancer · 3

Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors

2025 · Asli Özkan, Karlijn de Joode, et al. · European Journal of Cancer

Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors

2025 · Asli Özkan, Karlijn de Joode, et al. · European Journal of Cancer · 6

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry

2024 · A. Özkan, E. Kapiteijn, et al. · European Journal of Cancer · 14

Immunotherapy: should we worry about immunosenescence?

2024 · Asli Özkan, Nienke A. de Glas, et al. · Ageing and Cancer Research & Treatment · 1

Time Trends in Treatment Strategies and Survival of Older versus Younger Patients with Synchronous Metastasised Melanoma—A Population-Based Study in the Netherlands Cancer Registry

2022 · Daisy van der Ziel, Marloes G. M. Derks, et al. · Cancers · 4

Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

2021 · Nienke A. de Glas, Esther Bastiaannet, et al. · Cancers · 32